公开(公告)号：US09913604B2

公开(公告)日：2018-03-13

申请号：US14954869

申请日：2015-11-30

Applicant: OptiScan Biomedical Corporation

Inventor： James R. Braig ,  Peter Rule

IPC: A61B5/15 ,  A61B5/145 ,  A61B5/157 ,  A61B5/1455 ,  A61B5/00 ,  A61M5/172 ,  G01N21/27 ,  G06F19/00 ,  A61B5/153 ,  A61B5/155 ,  A61B5/1486 ,  A61M5/142 ,  A61M5/168 ,  A61M5/36 ,  A61M5/38 ,  G01N21/35

CPC classification number: A61B5/150992 ,  A61B5/14532 ,  A61B5/14546 ,  A61B5/1455 ,  A61B5/14557 ,  A61B5/1486 ,  A61B5/15003 ,  A61B5/150213 ,  A61B5/150221 ,  A61B5/150229 ,  A61B5/150267 ,  A61B5/150389 ,  A61B5/150503 ,  A61B5/150755 ,  A61B5/150854 ,  A61B5/153 ,  A61B5/155 ,  A61B5/157 ,  A61B5/4839 ,  A61M5/14212 ,  A61M5/14232 ,  A61M5/16854 ,  A61M5/1723 ,  A61M5/365 ,  A61M5/38 ,  A61M2205/12 ,  A61M2230/20 ,  A61M2230/201 ,  G01N21/274 ,  G01N21/35 ,  G01N2201/1293 ,  G06F19/00 ,  G06F19/3468 ,  G16H10/40 ,  G16H20/17

Abstract: In certain embodiments, a sampling assembly is for use with a main analyzer. The main analyzer is configured to sense an analyte in a body fluid obtained from a patient through a first fluid passageway extending from the main analyzer. The sampling assembly includes an instrument portion separate from the main analyzer and including at least one sensor. The instrument portion is removably engaged with the first fluid passageway. The at least one sensor is in sensing engagement with the first fluid passageway such that the at least one sensor can sense a property of a fluid within the first fluid passageway.

公开(公告)号：US09883830B2

公开(公告)日：2018-02-06

申请号：US15424337

申请日：2017-02-03

Applicant: OptiScan Biomedical Corporation

Inventor： Richard Keenan ,  Jeffrey Chiou ,  Jennifer Gable ,  Kenneth I-Shen Li ,  Roger Tong ,  Mike Recknor ,  James R. Braig

IPC: A61B5/157 ,  G01N33/50

CPC classification number: A61B5/157 ,  G01N33/50

Abstract: A fluid handling system for use in bodily fluid analysis. The system comprises a first fluid handling module configured to interface with a main instrument. The first fluid handling module has a first fluid handling network and the first fluid handling network includes an infusate passage and an infusion fluid pressure member suitable for moving fluid within the infusate passage. The fluid handling system also has a second fluid handling module separate from the first module which is configured to interface with the main instrument. The second fluid handling module has a second fluid handling network and at least one sample analysis cell which is accessible via the second fluid handling network. The first and second modules are configured to interconnect and provide fluid communication between the first and second fluid handling network and the sample cells.

公开(公告)号：US20170172480A1

公开(公告)日：2017-06-22

申请号：US15225079

申请日：2016-08-01

Applicant: OptiScan Biomedical Corporation

Inventor： James R. Braig ,  Peter Rule ,  Philip C. Hartstein ,  Bernhard B. Sterling ,  Jennifer H. Gable ,  Kenneth I. Li

IPC: A61B5/157 ,  G01N21/03 ,  A61B5/145 ,  G01N33/66 ,  A61B5/15 ,  A61B5/151 ,  A61B5/00 ,  G01N33/49 ,  G01N21/3577 ,  A61B5/1455

CPC classification number: A61B5/157 ,  A61B5/01 ,  A61B5/1411 ,  A61B5/14532 ,  A61B5/1455 ,  A61B5/150022 ,  A61B5/150083 ,  A61B5/150213 ,  A61B5/150358 ,  A61B5/150412 ,  A61B5/150458 ,  A61B5/150503 ,  A61B5/150618 ,  A61B5/150717 ,  A61B5/15087 ,  A61B5/151 ,  A61B5/15107 ,  A61B5/15136 ,  A61B5/1514 ,  A61B5/15194 ,  A61B5/6826 ,  A61B5/6838 ,  A61B10/0045 ,  A61B2562/0295 ,  A61B2562/12 ,  G01N21/03 ,  G01N21/0332 ,  G01N21/35 ,  G01N21/3577 ,  G01N21/3581 ,  G01N33/49 ,  G01N33/66 ,  G01N2021/0389 ,  G01N2201/02 ,  G01N2201/068

Abstract: A reagentless whole-blood analyte detection system that is capable of being deployed near a patient has a source capable of emitting a beam of radiation that includes a spectral band. The whole-blood system also has a detector in an optical path of the beam. The whole-blood system also has a housing that is configured to house the source and the detector. The whole-blood system also has a sample element that is situated in the optical path of the beam. The sample element has a sample cell and a sample cell wall that does not eliminate transmittance of the beam of radiation in the spectral band.

公开(公告)号：US09404852B2

公开(公告)日：2016-08-02

申请号：US14335491

申请日：2014-07-18

Applicant: OptiScan Biomedical Corporation

Inventor： James R. Braig ,  Peter Rule ,  Philip C. Hartstein ,  Bernhard B. Sterling ,  Jennifer H. Gable ,  Kenneth I. Li

IPC: G01N33/48 ,  G01N21/35 ,  A61B5/01 ,  A61B5/145 ,  A61B5/1455 ,  A61B5/00 ,  A61B5/151 ,  A61B5/157 ,  A61B10/00 ,  A61B5/15 ,  G01N21/03 ,  G01N21/3581

CPC classification number: A61B5/157 ,  A61B5/01 ,  A61B5/1411 ,  A61B5/14532 ,  A61B5/1455 ,  A61B5/150022 ,  A61B5/150083 ,  A61B5/150213 ,  A61B5/150358 ,  A61B5/150412 ,  A61B5/150458 ,  A61B5/150503 ,  A61B5/150618 ,  A61B5/150717 ,  A61B5/15087 ,  A61B5/151 ,  A61B5/15107 ,  A61B5/15136 ,  A61B5/1514 ,  A61B5/15194 ,  A61B5/6826 ,  A61B5/6838 ,  A61B10/0045 ,  A61B2562/0295 ,  A61B2562/12 ,  G01N21/03 ,  G01N21/0332 ,  G01N21/35 ,  G01N21/3577 ,  G01N21/3581 ,  G01N33/49 ,  G01N33/66 ,  G01N2021/0389 ,  G01N2201/02 ,  G01N2201/068

Abstract: A reagentless whole-blood analyte detection system that is capable of being deployed near a patient has a source capable of emitting a beam of radiation that includes a spectral band. The whole-blood system also has a detector in an optical path of the beam. The whole-blood system also has a housing that is configured to house the source and the detector. The whole-blood system also has a sample element that is situated in the optical path of the beam. The sample element has a sample cell and a sample cell wall that does not eliminate transmittance of the beam of radiation in the spectral band.

Abstract translation: 能够在患者附近部署的无试剂全血分析物检测系统具有能够发射包括光谱带的辐射束的源。 全血系统还具有光束的光路中的检测器。 全血系统还具有容纳源和检测器的壳体。 全血系统还具有位于束的光路中的样品元件。 样品元件具有不消除光谱带中的辐射束的透射率的样品池和样品池壁。

公开(公告)号：US20160157768A1

公开(公告)日：2016-06-09

申请号：US14954869

申请日：2015-11-30

Applicant: OptiScan Biomedical Corporation

Inventor： James R. Braig ,  Peter Rule

IPC: A61B5/15 ,  A61B5/145 ,  A61B5/157 ,  A61B5/1455

CPC classification number: A61B5/150992 ,  A61B5/14532 ,  A61B5/14546 ,  A61B5/1455 ,  A61B5/14557 ,  A61B5/1486 ,  A61B5/15003 ,  A61B5/150213 ,  A61B5/150221 ,  A61B5/150229 ,  A61B5/150267 ,  A61B5/150389 ,  A61B5/150503 ,  A61B5/150755 ,  A61B5/150854 ,  A61B5/153 ,  A61B5/155 ,  A61B5/157 ,  A61B5/4839 ,  A61M5/14212 ,  A61M5/14232 ,  A61M5/16854 ,  A61M5/1723 ,  A61M5/365 ,  A61M5/38 ,  A61M2205/12 ,  A61M2230/20 ,  A61M2230/201 ,  G01N21/274 ,  G01N21/35 ,  G01N2201/1293 ,  G06F19/00 ,  G06F19/3468 ,  G16H10/40 ,  G16H20/17

Abstract: In certain embodiments, a sampling assembly is for use with a main analyzer. The main analyzer is configured to sense an analyte in a body fluid obtained from a patient through a first fluid passageway extending from the main analyzer. The sampling assembly includes an instrument portion separate from the main analyzer and including at least one sensor. The instrument portion is removably engaged with the first fluid passageway. The at least one sensor is in sensing engagement with the first fluid passageway such that the at least one sensor can sense a property of a fluid within the first fluid passageway.

Abstract translation: 在某些实施例中，采样组件用于主分析器。 主分析器构造成通过从主分析器延伸的第一流体通道感测从患者获得的体液中的分析物。 采样组件包括与主分析器分离并且包括至少一个传感器的仪器部分。 仪器部分可移除地与第一流体通道接合。 所述至少一个传感器与第一流体通道感应接合，使得至少一个传感器可感测第一流体通道内的流体的特性。

公开(公告)号：US09302045B2

公开(公告)日：2016-04-05

申请号：US13857949

申请日：2013-04-05

Applicant: OPTISCAN BIOMEDICAL CORPORATION

Inventor： Peter Rule

IPC: A61B5/00 ,  A61M31/00 ,  A61M5/172 ,  A61B5/155 ,  A61B5/145 ,  A61B5/1455 ,  G06F19/00 ,  A61M5/168 ,  A61M5/14 ,  A61M5/142

CPC classification number: A61M5/1723 ,  A61B5/1427 ,  A61B5/14532 ,  A61B5/14535 ,  A61B5/14546 ,  A61B5/14557 ,  A61B5/15003 ,  A61B5/150221 ,  A61B5/150229 ,  A61B5/150305 ,  A61B5/150389 ,  A61B5/150503 ,  A61B5/150755 ,  A61B5/150786 ,  A61B5/150862 ,  A61B5/155 ,  A61B5/157 ,  A61B5/412 ,  A61B5/4839 ,  A61B5/7475 ,  A61M5/1415 ,  A61M5/142 ,  A61M5/16827 ,  A61M2005/1404 ,  A61M2005/14208 ,  A61M2005/1726 ,  A61M2205/12 ,  A61M2205/18 ,  A61M2205/3313 ,  A61M2205/3569 ,  A61M2205/502 ,  A61M2205/52 ,  A61M2230/005 ,  A61M2230/201 ,  G06F19/00 ,  G06F19/3468

Abstract: Disclosed are methods and apparatuses for determining analyte concentration in a sample such as bodily fluid. Systems and methods disclosed herein can also include a treatment dosing system to infuse or inject a treatment dose (e.g. insulin, dextrose, etc.) and provide glycemic control. The dose of the treatment drug may be based on the patient's calculated sensitivity to treatment dosing, for example. The dose of the treatment drug may be based on the concentration of the analyte or the average value for the concentration of the analyte and/or the rate of change of the value of the concentration of the analyte. Delivery of the treatment drug can be cut off if the determined analyte concentration indicates that continued delivery would be harmful to the patient.

公开(公告)号：US20150157249A1

公开(公告)日：2015-06-11

申请号：US14598111

申请日：2015-01-15

Applicant: OptiScan Biomedical Corporation

Inventor： Jennifer H. Gable ,  James R. Braig ,  Kenneth I. Li ,  Mark Wechsler ,  Peng Zheng ,  Richard Keenan

IPC: A61B5/157 ,  A61B5/15 ,  G01N21/3577

CPC classification number: A61B5/157 ,  A61B5/0071 ,  A61B5/0075 ,  A61B5/0084 ,  A61B5/0086 ,  A61B5/1411 ,  A61B5/1427 ,  A61B5/1451 ,  A61B5/14517 ,  A61B5/14532 ,  A61B5/14535 ,  A61B5/14546 ,  A61B5/1455 ,  A61B5/15003 ,  A61B5/150213 ,  A61B5/150221 ,  A61B5/150229 ,  A61B5/150267 ,  A61B5/150358 ,  A61B5/150755 ,  A61B5/150862 ,  A61B5/150992 ,  A61B5/153 ,  A61B5/155 ,  A61B5/4839 ,  A61B10/0064 ,  A61B2560/0443 ,  A61M5/14212 ,  A61M5/14232 ,  A61M5/16854 ,  A61M5/1723 ,  A61M5/365 ,  A61M5/38 ,  A61M2205/12 ,  A61M2205/3306 ,  A61M2230/20 ,  A61M2230/201 ,  G01N21/03 ,  G01N21/3577 ,  G01N2021/3595 ,  G01N2201/02 ,  G01N2201/061 ,  G06F19/00 ,  Y10T137/4478 ,  Y10T137/7722 ,  Y10T137/86485 ,  Y10T436/111666 ,  Y10T436/2575

Abstract: Disclosed is an apparatus for analyzing the composition of bodily fluid. The apparatus can include a fluid handling network including a patient end configured to maintain fluid communication with a bodily fluid in a patient and a pump unit in operative engagement with the fluid handling network. The pump unit can have an infusion mode, in which the pump unit is operable to deliver infusion fluid to the patient through the patient end, and a sample draw mode, in which the pump unit is operable to draw a sample of the bodily fluid from the patient through the patient end. The apparatus can include a spectroscopic analyzer positioned to analyze at least a portion of the sample; a processor in communication with or incorporated into the spectroscopic analyzer; and stored program instructions executable by the processor to obtain measurements of two or more properties of the sample.

Abstract translation: 公开了一种用于分析体液组成的装置。 该装置可以包括流体处理网络，其包括被配置为保持与患者体内的体液的流体连通的患者端和与流体处理网络可操作地接合的泵单元。 泵单元可以具有输注模式，其中泵单元可操作以通过患者端向患者输送输注流体，以及抽样模式，其中，泵单元可操作以从体外抽取体液样本 患者通过病人结束。 该装置可以包括定位成分析样品的至少一部分的光谱分析仪; 与光谱分析仪通信或并入其中的处理器; 以及可由处理器执行的存储的程序指令，以获得样本的两个或多个属性的测量。

公开(公告)号：US20140275868A1

公开(公告)日：2014-09-18

申请号：US14088076

申请日：2013-11-22

Applicant: OptiScan Biomedical Corporation

Inventor： Peter Rule ,  Gil Rivas

IPC: A61B5/15 ,  A61B5/157

CPC classification number: G06F19/3412 ,  A61B5/0002 ,  A61B5/1427 ,  A61B5/14532 ,  A61B5/14546 ,  A61B5/1455 ,  A61B5/14557 ,  A61B5/1459 ,  A61B5/1495 ,  A61B5/15003 ,  A61B5/150213 ,  A61B5/150221 ,  A61B5/150229 ,  A61B5/150305 ,  A61B5/150389 ,  A61B5/150503 ,  A61B5/150755 ,  A61B5/150992 ,  A61B5/155 ,  A61B5/157 ,  A61B5/412 ,  A61B5/4839 ,  A61B5/7435 ,  A61B5/7475 ,  A61B2560/0271 ,  A61B2560/029 ,  A61B2560/0437 ,  A61M5/1415 ,  A61M5/16827 ,  A61M5/1723 ,  A61M2005/1404 ,  A61M2005/14208 ,  A61M2005/1726 ,  A61M2205/12 ,  A61M2205/6072 ,  A61M2230/201 ,  G01N21/274 ,  G01N21/35 ,  G01N21/3577 ,  G01N21/359 ,  G01N33/49 ,  G06F19/00 ,  G06F19/3418 ,  G06F19/3468 ,  G06F19/3487 ,  G16H15/00 ,  G16H40/40

Abstract: Some embodiments provide a system for synchronizing and configuring monitoring devices. In some embodiments, a patient monitoring device settings module is configured to automatically provide configuration settings to a plurality of patient monitoring devices. A monitoring device data module is configured to receive measurement data from at least one of the patient monitoring devices. An electronic medical records system interface is configured to provide patient data at least partially derived from the received measurement data to an electronic medical records system. A patient records interface is configured to provide patient data to at least one of the patient monitoring devices.

Abstract translation: 一些实施例提供用于同步和配置监视设备的系统。 在一些实施例中，患者监视设备设置模块被配置为自动地向多个患者监视设备提供配置设置。 监视设备数据模块被配置为从至少一个患者监视设备接收测量数据。 电子医疗记录系统接口被配置为将至少部分地从接收到的测量数据导出的患者数据提供给电子病历系统。 患者记录界面被配置为向至少一个患者监视设备提供患者数据。

公开(公告)号：US20140066844A1

公开(公告)日：2014-03-06

申请号：US13857949

申请日：2013-04-05

Applicant: OPTISCAN BIOMEDICAL CORPORATION

Inventor： Peter Rule

IPC: A61M5/172

CPC classification number: A61M5/1723 ,  A61B5/1427 ,  A61B5/14532 ,  A61B5/14535 ,  A61B5/14546 ,  A61B5/14557 ,  A61B5/15003 ,  A61B5/150221 ,  A61B5/150229 ,  A61B5/150305 ,  A61B5/150389 ,  A61B5/150503 ,  A61B5/150755 ,  A61B5/150786 ,  A61B5/150862 ,  A61B5/155 ,  A61B5/157 ,  A61B5/412 ,  A61B5/4839 ,  A61B5/7475 ,  A61M5/1415 ,  A61M5/142 ,  A61M5/16827 ,  A61M2005/1404 ,  A61M2005/14208 ,  A61M2005/1726 ,  A61M2205/12 ,  A61M2205/18 ,  A61M2205/3313 ,  A61M2205/3569 ,  A61M2205/502 ,  A61M2205/52 ,  A61M2230/005 ,  A61M2230/201 ,  G06F19/00 ,  G06F19/3468

Abstract: Disclosed are methods and apparatuses for determining analyte concentration in a sample such as bodily fluid. Systems and methods disclosed herein can also include a treatment dosing system to infuse or inject a treatment dose (e.g. insulin, dextrose, etc.) and provide glycemic control. The dose of the treatment drug may be based on the patient's calculated sensitivity to treatment dosing, for example. The dose of the treatment drug may be based on the concentration of the analyte or the average value for the concentration of the analyte and/or the rate of change of the value of the concentration of the analyte. Delivery of the treatment drug can be cut off if the determined analyte concentration indicates that continued delivery would be harmful to the patient.

Abstract translation: 公开了用于测定诸如体液的样品中的分析物浓度的方法和装置。 本文公开的系统和方法还可以包括注射或注射治疗剂量（例如胰岛素，葡萄糖等）并提供血糖控制的治疗剂量系统。 治疗药物的剂量可以基于例如患者对治疗剂量的计算灵敏度。 治疗药物的剂量可以基于分析物的浓度或分析物浓度的平均值和/或分析物浓度值的变化率。 如果确定的分析物浓度表明持续传递对患者有害，则可以切断治疗药物的递送。